BridgeBio Pharma Business Summary

BridgeBio Pharma, Inc. (BBIO) operates as a commercial-stage biopharmaceutical company utilizing a decentralized "hub-and-spoke" model to develop and commercialize therapies for genetic diseases and precision oncology. The company generates revenue primarily through net product sales of its flagship stabilizer, Attruby (acoramidis), which achieved preliminary 2025 revenues of $362.4 million following its launch for transthyretin amyloid cardiomyopathy (ATTR-CM). Additional revenue is derived from strategic licensing agreements and milestone payments from partners like Bayer and Bristol Myers Squibb. BridgeBio’s primary business segments are organized around therapeutic categories, including Mendelian disorders, oncology, and gene therapy. The company competes directly with rare-disease specialists such as Alnylam Pharmaceuticals, BioMarin Pharmaceutical, and Ascendis Pharma, positioning itself as a high-growth, multi-asset enterprise targeting non-GAAP profitability by the fourth quarter of 2026. The leadership team is led by Co-Founder and CEO Dr. Neil Kumar, who brings a pedigree from Third Rock Ventures, MyoKardia, and McKinsey & Company. He is supported by Co-Founder and Chairman of Oncology Dr. Frank McCormick, a former President of the AACR, and Chairman of Pharmaceuticals Dr. Charles Homcy, a veteran of Portola Pharmaceuticals and Third Rock. Other key executives include CFO and President Thomas Trimarchi, Chief Scientific Officer Dr. Uma Sinha, and Chairman of R&D Dr. Richard Scheller, a Lasker Award winner and former head of research at Genentech. The company maintains a high-profile investor base and board, featuring significant positions from KKR and Viking Global Investors, with notable board members including Fred Hassan, the former CEO of Schering-Plough, and Ali Satvat, Co-Head of Healthcare at KKR.